Zembrace SymTouch FDA Approval History
FDA Approved: Yes (First approved January 28, 2016)
Brand name: Zembrace SymTouch
Generic name: sumatriptan
Dosage form: Injection
Company: Dr. Reddy's Laboratories, Inc.
Treatment for: Migraine
Zembrace SymTouch (sumatriptan) is a selective 5-HT1B/ID receptor agonist in a prefilled, ready-to-use, single-dose disposable autoinjector for the treatment of acute migraine episodes, with or without aura.
Development timeline for Zembrace SymTouch
| Date | Article |
|---|---|
| Jan 29, 2016 | Approval Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
